top of page

After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future

blonca9
Jul 23
1 min read

CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.

Recent Posts

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S.

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region

Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page